BRPI0911511B8 - formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo - Google Patents

formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo

Info

Publication number
BRPI0911511B8
BRPI0911511B8 BRPI0911511A BRPI0911511A BRPI0911511B8 BR PI0911511 B8 BRPI0911511 B8 BR PI0911511B8 BR PI0911511 A BRPI0911511 A BR PI0911511A BR PI0911511 A BRPI0911511 A BR PI0911511A BR PI0911511 B8 BRPI0911511 B8 BR PI0911511B8
Authority
BR
Brazil
Prior art keywords
dna
lyophilized
formulation
plasmid dna
expression
Prior art date
Application number
BRPI0911511A
Other languages
English (en)
Inventor
Kim Jong-Mook
Kim Sujeong
Yoo Wonsun
Hahn Woong
Original Assignee
Helixmith Co Ltd
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helixmith Co Ltd, Viromed Co Ltd filed Critical Helixmith Co Ltd
Publication of BRPI0911511A2 publication Critical patent/BRPI0911511A2/pt
Publication of BRPI0911511B1 publication Critical patent/BRPI0911511B1/pt
Publication of BRPI0911511B8 publication Critical patent/BRPI0911511B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulações de dna liofilizadas para aumentar a expressão de dna de plasmídeo. a presente invenção fornece uma formulação de dna liofilizada a partir de uma composição compreendendo um dna de plasmídeo, um sal e um carboidrato, em que o referido dna de plasmídeo compreende um gene hgf, ou variante do mesmo.
BRPI0911511A 2008-04-09 2009-04-09 formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo BRPI0911511B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4360508P 2008-04-09 2008-04-09
US61/043,605 2008-04-09
PCT/KR2009/001831 WO2009125986A2 (en) 2008-04-09 2009-04-09 Lyophilized dna formulations for enhanced expression of plasmid dna

Publications (3)

Publication Number Publication Date
BRPI0911511A2 BRPI0911511A2 (pt) 2016-05-17
BRPI0911511B1 BRPI0911511B1 (pt) 2021-01-05
BRPI0911511B8 true BRPI0911511B8 (pt) 2021-05-25

Family

ID=41162399

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911511A BRPI0911511B8 (pt) 2008-04-09 2009-04-09 formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo

Country Status (12)

Country Link
US (2) US20090258932A1 (pt)
EP (1) EP2281040B1 (pt)
JP (1) JP5579164B2 (pt)
KR (1) KR101290322B1 (pt)
CN (1) CN102046792B (pt)
AU (1) AU2009234598C1 (pt)
BR (1) BRPI0911511B8 (pt)
CA (1) CA2720611C (pt)
ES (1) ES2556711T3 (pt)
MX (1) MX2010010993A (pt)
RU (1) RU2470995C2 (pt)
WO (1) WO2009125986A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
KR101290322B1 (ko) * 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2014056590A1 (en) 2012-10-08 2014-04-17 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
PT3247719T (pt) 2015-01-21 2019-12-23 Univ Degli Studi Di Pavia Proteínas agonistas do receptor met
CN106282227B (zh) * 2015-06-09 2022-02-08 北京诺思兰德生物技术股份有限公司 一种重组人肝细胞生长因子裸质粒的高密度发酵方法
SG11202006169PA (en) * 2017-12-29 2020-07-29 Helixmith Co Ltd Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
US11510999B2 (en) 2018-07-17 2022-11-29 Helixmith Co., Ltd Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
AU2019305221B2 (en) * 2018-07-19 2024-11-07 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy
CN110511926B (zh) * 2019-09-06 2021-11-30 郑州安图生物工程股份有限公司 一种质粒、假病毒的保存液及其用途
EP4501312A4 (en) * 2022-03-24 2025-06-25 Helixmith Co., Ltd PHARMACEUTICAL COMPOSITION OF LIQUID FORMULATION COMPRISING PLASMIDIC DNA
WO2024059819A2 (en) 2022-09-15 2024-03-21 Tff Pharmaceuticals, Inc. Compositions of cannabinoids for delivery by inhalation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
ATE178354T1 (de) * 1990-07-13 1999-04-15 Snow Brand Milk Products Co Ltd Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US7323297B1 (en) * 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EP0872249A4 (en) * 1995-03-17 2001-10-24 Hisamitsu Pharmaceutical Co GENE TRANSFER PREPARATION
JP2001516329A (ja) * 1995-06-07 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリヌクレオチド複合体の安定化
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
KR100765687B1 (ko) * 1995-08-29 2007-10-11 안제스에무지 가부시키가이샤 Ｈｇｆ 유전자를 함유하는 약제
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
KR20010012313A (ko) 1997-05-06 2001-02-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 혈관형성성 트랜스유전자의 생체내 송달에 의한 심장 질환및 심실 리모델링을 치료하기 위한 방법 및 조성물
WO1999045775A1 (en) 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US7276359B1 (en) * 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
EP1555033A3 (en) * 1998-03-13 2005-08-17 Wyeth Polynucleotide composition, method of preparation, and use thereof
ATE294594T1 (de) * 1998-03-13 2005-05-15 Wyeth Corp Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung
ATE409494T1 (de) * 1999-10-29 2008-10-15 Anges Mg Inc Gentherapie für diabetische ischämie
JP2003513942A (ja) 1999-11-05 2003-04-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ遺伝子送達による心血管疾患を処理するための技術および組成物
AU2001266338B8 (en) * 2000-06-27 2006-12-14 Anges Mg, Inc. Pharmaceutical compositions for angiogenic therapy
US20030176347A1 (en) * 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
CN1150035C (zh) 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
CA2508279A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
CA2536931A1 (en) * 2003-09-17 2005-03-24 Centelion Method of preparation of pharmaceutically grade plasmid dna
US20050164208A1 (en) * 2004-01-22 2005-07-28 Paul Poulin Storage of genetic information
WO2007132873A1 (ja) * 2006-05-17 2007-11-22 Yoshiyuki Koyama 核酸、オリゴ核酸、又はその誘導体導入用の凍結乾燥体
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
KR101290322B1 (ko) 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제

Also Published As

Publication number Publication date
JP5579164B2 (ja) 2014-08-27
AU2009234598A1 (en) 2009-10-15
HK1155776A1 (zh) 2012-05-25
KR101290322B1 (ko) 2013-07-26
ES2556711T3 (es) 2016-01-19
EP2281040A2 (en) 2011-02-09
CN102046792A (zh) 2011-05-04
EP2281040A4 (en) 2011-10-12
US20090258932A1 (en) 2009-10-15
RU2470995C2 (ru) 2012-12-27
KR20100129341A (ko) 2010-12-08
CA2720611A1 (en) 2009-10-15
AU2009234598C1 (en) 2012-08-23
AU2009234598B2 (en) 2011-07-14
JP2011516545A (ja) 2011-05-26
US8389492B2 (en) 2013-03-05
EP2281040B1 (en) 2015-11-25
WO2009125986A3 (en) 2010-01-14
CN102046792B (zh) 2014-12-10
CA2720611C (en) 2016-07-12
RU2010145261A (ru) 2012-05-20
WO2009125986A2 (en) 2009-10-15
MX2010010993A (es) 2010-11-05
US20110166211A1 (en) 2011-07-07
BRPI0911511B1 (pt) 2021-01-05
BRPI0911511A2 (pt) 2016-05-17

Similar Documents

Publication Publication Date Title
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112016003127A2 (pt) “composições e métodos para modular rna”
MX374694B (es) USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS.
ECSP14028051A (es) Compuestos d-aminoácidos para enfermedad hepática
WO2009125986A3 (en) Lyophilized dna formulations for enhanced expression of plasmid dna
CR11031A (es) Composiciones de enzima digestiva estable
BRPI0710508B8 (pt) composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
BR112015000161A2 (pt) composições de vetor de vírus adeno-associado modificado
MX2009012588A (es) Composicion acondicionadora del cabello que comprende polimero de silicona cuaternizado, copoliol de silicona injertado y surfactante cationico dialquilo.
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BRPI0923731A2 (pt) "formulações injetáveis de toxinas botulínicas".
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
MY156951A (en) Micromirs
BR112012026724A2 (pt) combinação de fármcos com pró-fármacos ligados à proteína
BRPI0514766A (pt) composições farmacêuticas
BR112014027995A2 (pt) uso de seaprose para remover biopelícula bacteriana
BR112014032759A2 (pt) composições lipídicas de racecadotril

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HELIXMITH CO., LTD (KR)

B25G Requested change of headquarter approved

Owner name: HELIXMITH CO., LTD (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO DO QUADRO 1

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF